Video

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

In April 2019, we announced a collaboration with AstraZeneca to design and develop new treatments for disease beginning with chronic kidney disease and idiopathic pulmonary fibrosis.

By combining our AI and machine learning capabilities with AstraZeneca’s disease area expertise and large, diverse datasets, we hope to improve our understanding of complex disease biology and more quickly identify new potential drug targets.

Our biologists, chemists, engineers, informaticians and data scientists, are working together with our peers at AstraZeneca  to provide new opportunities in understanding and targeting these diseases. In this video, scientists from the centre of the project chart the progress of the collaboration and share their reflections on changing the way we do drug discovery, to enable more efficient and data-driven development  of new medicines.

In our opinion,  partnerships aren’t forged on paper. You can’t write a partnership into being. It has to be based on a professional respect, shared ambition and a common set of values. For us this is the fusion of human expertise with technological innovation. That collision of capabilities is what will help us work  together to  help more people live longer, healthier lives.


More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022